Yazar "Boormans, Joost L." için listeleme
-
Prognostic factor risk groups for clinical stage ı seminoma: An individual patient data analysis by the european association of urology testicular cancer guidelines panel and guidelines office
Boormans, Joost L.; Sylvester, Richard; Anson Cartwright, Lynn; Glicksman, Rachel M.; Hamilton, Robert J.; Hahn, Ezra; Daugaard, Gedske; Lauritsen, Jakob; Wagner, Thomas; Avuzzi, Barbara; Nicolai, Nicola; Del Muro, Xavier García; Aparicio, Jorge; Stalder, Odile; Rothermundt, Christian; Fischer, Stefanie; del Pilar Laguna Pes, Maria (2024)BACKGROUND: The relapse rate in patients with clinical stage I (CSI) seminomatous germ cell tumor of the testis (SGCTT) who were undergoing surveillance after radical orchidectomy is 4-30%, depending on tumor size and rete ... -
Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Fankhauser, Christian Daniel; Oldenburg, Jan; Albers, Peter; Algaba, Ferran; Bokemeyer, Carsten; Boormans, Joost L.; Fischer, Stefanie; Fizazi, Karim; Gremmels, Hendrik; Mayor de Castro, Javier; Janisch, Florian; Muilwijk, Tim; Leao, Ricardo; Nicol, David; Nicolai, Nicola; Tandstad, Torgrim; del Pilar Laguna Pes, Maria (Elsevier, 2021)Recent randomized controlled trials have assessed the risksand benefits of thromboprophylaxis in ambulatory cancerpatients receiving chemotherapy and reported a relativerisk reduction of 30–60% in venous thromboembolic ...